eurekalert.org
May 5, 2008
Biotech and pharma companies are increasingly utilizing novel technologies to assess the druggability of test compounds early in the development cycle to avoid costly late clinical-stage attrition, according to Genetic Engineering and Biotechnology News. By identifying absorption, distribution,...
[read full story]